At ASH 2025, CAR-T felt less like an experimental frontier and more like a maturing modality struggling to keep pace with its own promise. Guidelines now favor CAR-T in first-line multiple myeloma for eligible patients and momentum is building toward earlier use in lymphoma, while data on next-generation multi-targeted and in vivo constructs alongside improved manufacturing platforms signal progress on durability, toxicity, and decreased vein-to-vein time. Notably, ASH dedicated oral presentation slots to CAR-T in autoimmune diseases, a striking departure that signals the field’s recognition of cell therapies as a platform technology extending well beyond hematologic malignancies
What emerged most clearly across sessions was a fundamental shift in the drivers of future cell therapy success.
- Determinants of clinical outcomes: Optimal outcomes are increasingly predicated on upstream biological and logistical variables, specifically earlier treatment initiation, preservation of T-cell fitness, optimized bridging strategies, and minimized vein-to-vein intervals rather than product efficacy and label alone.
- Operational and access dynamics: Effective delivery relies on coordinated hub-and-spoke models to manage complex care transitions supported by clear reimbursement pathways and payer navigation for patients. While navigation strategies for vulnerable patients are advancing to address access equity, achieving true “community-ready” status remains a strategic ambition limited by persistent gaps in standardized workflows, coding frameworks, reimbursement alignment, and clearly defined roles and reporting standards across hub-and-spoke networks.
- Evolving regulatory paradigm: The regulatory landscape presents competing pressures: the removal of REMS for established therapies signals safety and maturity and enables decentralized care, while new FDA guidance elevates evidentiary thresholds, preferring randomized, placebo-controlled trials over historical single-arm approvals, raising the bar for differentiation.
- Competitive differentiation: Bispecific antibodies alone or as part of combination regimens (eg, teclistamab plus daratumumab) are redefining therapeutic paradigms. Market differentiation now demands integrated strategies beyond clinical efficacy, emphasizing operational feasibility, manufacturing innovation, and alignment with evolving regulatory and payer expectations.
- Patient engagement: Patient and caregiver perspectives must be systematically integrated into access design and support strategies, not just clinical decision-making. Understanding what patients and caregivers need to navigate referral, treatment decisions, and the CAR-T journey is essential to closing the gap between eligibility and actual infusion. As CAR-T increasingly shifts toward outpatient delivery, ensuring adequate patient and caregiver support remains essential to sustainable access.
- Narrative and positioning: Translating complex CAR-T science into coherent, differentiated stories across indications, modalities, and stakeholder audiences.
- Cross-functional integration: Bridging medical affairs, market access, and commercial strategy to align science, evidence, and adoption pathways, including the design of sponsor-supported education, care coordination, and implementation tools that extend beyond the product itself.
- Evidence strategy: Designing clinical, real-world, and operational data programs that de-risk earlier use and meet evolving regulatory and payer expectations.
- Patient-centered strategy: Embedding patient and caregiver insights into access design, education, and decision support.
